A growing body of evidence suggests that tumor mutational burden (TMB), interferon pathway defects, baseline CD8+ T cell infiltration, PD-L1 expression, and gut microbiota composition may modulate OV efficacy [22,23,24]. The gene discussed is CD8A; the disease is neoplasm.